Epilepsy Drug Linked To Blood Disorder: FDA

Law360, New York (February 23, 2009, 12:00 AM EST) -- The epilepsy drug zonisamide — marketed under the brand name Zonegran by Eisai Co. Ltd. and sold in generic form by Teva Pharmaceutical Industries Ltd., Mylan Inc., Novartis AG’s Sandoz unit and Watson Pharmaceuticals Inc. — has come under fire by federal health regulators, who warned Monday the medication can cause a serious blood disorder known as metabolic acidosis in some patients.

The U.S. Food and Drug Administration said it had made the determination following a review of updated clinical data related to zonisamide, which is...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.